[HTML][HTML] Left ventricular restoration devices post myocardial infarction
T Hendriks, RAJ Schurer, L Al Ali… - Heart failure …, 2018 - Springer
Even in the era of percutaneous reperfusion therapy, left ventricular (LV) remodeling after
myocardial infarction (MI) leading to heart failure remains a major health concern …
myocardial infarction (MI) leading to heart failure remains a major health concern …
[HTML][HTML] Prognostic implications for patients after myocardial infarction: an integrative literature review and in-depth interviews with patients and experts
SY Hwang, SH Kim, IA Uhm, JH Shin… - BMC Cardiovascular …, 2022 - Springer
Background As patients with myocardial infarction (MI) survive for a long time after acute
treatment, it is necessary to pay attention to the prevention of poor prognosis such as heart …
treatment, it is necessary to pay attention to the prevention of poor prognosis such as heart …
[HTML][HTML] C-reactive protein as a risk marker for post-infarct heart failure over a multi-year period
I Świątkiewicz, P Magielski, J Kubica - International Journal of Molecular …, 2021 - mdpi.com
Inflammatory activation during acute ST-elevation myocardial infarction (STEMI) can
contribute to post-infarct heart failure (HF). This study aimed to determine prognostic value of …
contribute to post-infarct heart failure (HF). This study aimed to determine prognostic value of …
[PDF][PDF] 可溶性生长刺激表达基因2 蛋白和MHR 及NLR 在重症心力衰竭中的相关性研究
齐晓瑜， 李敬， 张羽， 李娜， 孙红春， 李英， 付建平… - 临床急诊杂志, 2022 - whuhzzs.com
目的: 探讨可溶性生长刺激表达基因2 蛋白(sST2), 单核细胞与高密度脂蛋白胆固醇比值(MHR)
和中性粒细胞与淋巴细胞比值(NLR) 在重症心力衰竭表达的相关性研究. 方法: 分析2017 年12 …
和中性粒细胞与淋巴细胞比值(NLR) 在重症心力衰竭表达的相关性研究. 方法: 分析2017 年12 …
[HTML][HTML] Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
H Watanabe, N Ozasa, T Morimoto, H Shiomi… - PLoS …, 2018 - journals.plos.org
Background Despite its recommendation by the current guidelines, the role of long-term oral
beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST …
beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST …
Heart failure incidence following ST-elevation myocardial infarction
R Costa, M Trêpa, M Oliveira, A Frias… - The American journal of …, 2022 - Elsevier
ST-elevation myocardial infarction (STEMI) survivors have a heightened risk of developing
heart failure (HF). The magnitude of this risk with the advent of primary percutaneous …
heart failure (HF). The magnitude of this risk with the advent of primary percutaneous …
Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors
JMIH Gho, PG Postema, M Conijn, N Bruinsma… - Open …, 2017 - openheart.bmj.com
Objective The aim of the current study was to determine the contemporary incidence, risk
factors and prognosis of heart failure (HF) after ST-elevation myocardial infarction (STEMI) …
factors and prognosis of heart failure (HF) after ST-elevation myocardial infarction (STEMI) …
Prognostic value of natriuretic peptide levels and in-hospital heart failure events in patients with acute myocardial infarction
K Asada, Y Saito, T Sato, T Matsumoto… - Circulation …, 2023 - jstage.jst.go.jp
Background: In patients with acute myocardial infarction (AMI), elevated natriuretic peptide
(NP) concentrations are reportedly associated with worse clinical outcomes. This study …
(NP) concentrations are reportedly associated with worse clinical outcomes. This study …
[HTML][HTML] Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury
Background This study tested whether combined dapagliflozin and entresto treatment would
be superior to either one alone for preserving the left-ventricular ejection-fraction (LVEF) in …
be superior to either one alone for preserving the left-ventricular ejection-fraction (LVEF) in …
[HTML][HTML] Therapeutic effects of adipose derived fresh stromal vascular fraction-containing stem cells versus cultured adipose derived mesenchymal stem cells on …
JJ Sheu, MS Lee, CG Wallace, KH Chen… - American journal of …, 2019 - ncbi.nlm.nih.gov
We tested the hypothesis that adipose-derived fresh stromal vascular fraction (SVF) is non-
inferior to conventional adipose-derived mesenchymal stem cell (ADMSC) therapy for …
inferior to conventional adipose-derived mesenchymal stem cell (ADMSC) therapy for …